Eevia Health Plc ("Eevia" or "The Company") is welcoming Dr. Tommi Kilpeläinen asits new Scientific Product Manager.
Tommi Kilpeläinen is educated as a Doctor of Pharmacy (Ph.D.) in pharmacology and pharmaceutical chemistry, and he is also a certified pharmacist. He will head the strategic positioning of Eevia Health's nutraceutical product portfolio and spearhead Eevia's strategy to become a leader in products aimed to support and enhance cellular recycling to maintain healthy cell function.
Dr. Kilpeläinen started in the new position in Eevia in October 2022 and is working full-time for Eevia Health as a member of the Senior Leader Team. Before joining Eevia Health, he worked as a post-doctoral researcher at the University of Helsinki, where he managed research in neuroscience and lead compound discovery. He has special skills related to autophagy processes in human cells and, molecular biology methods and pre-clinical animal models.
"We are very pleased to welcome Tommi to bring our products to the forefront of the nutraceutical industry. The strategic choice Eevia Health is making to focus on extracts that support cellular health and autophagy is a perfect match with Dr. Kilpeläinens's expertise and research background. The demand for products with efficacy in autophagy induction (cellular recycling), and cognitive health will skyrocket in the future. Eevia Health will position itself to be a leading ingredient provider within this category and Tommi will contribute to our Team's ability to execute this strategy," comments Stein Ulve, CEO of Eevia Health Plc.
Dr. Kilpeläinen explains his interest in Eevia Health: I am a scientifically oriented person with a great interest in lead compound development, in which I can use my innovative and productive approach and passion for finding new solutions and applications. Eevia Health has an inspiring mission to valorize solutions from science on natural plant extracts and turn this into commercial products and contribute to people's health and well-being.
For further information, please contact:
Stein Ulve, CEO, Eevia Health Plc
Email: stein.ulve@eeviahealth.com
Telephone: +358 400 22 5967
INFORMATION ABOUT EEVIA HEALTH PLC
Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients in dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.
Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.
Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name EEVIA.
To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.